Biomea Fusion Stock (NASDAQ:BMEA)

Forecast Revenue Ownership Financials Chart

Previous Close

$6.42

52W Range

$3.61 - $22.74

50D Avg

$9.50

200D Avg

$10.21

Market Cap

$227.58M

Avg Vol (3M)

$819.64K

Beta

-0.43

Div Yield

-

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-126.14M	$-83.63M	$-41.67M
Net Income	$-117.25M	$-80.02M	$-41.22M
EBITDA	$-121.93M	$-83.63M	$-41.67M
Basic EPS	$-3.44	$-2.73	$-1.73
Diluted EPS	$-3.44	$-2.73	$-1.73

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
CGEM	Cullinan Oncology, Inc.
IKNA	Ikena Oncology, Inc.
EWTX	Edgewise Therapeutics, Inc.
DSGN	Design Therapeutics, Inc.
HOWL	Werewolf Therapeutics, Inc.